PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT
INTERNAL MEMORANDUM
FROM: Simone Laroche, Senior Associate, Calderwood & Harkness LLP Jeffrey Park, Associate, Calderwood & Harkness LLP
TO: Theodore Langston, Partner, Calderwood & Harkness LLP Vivienne St. Claire, Partner, Calderwood & Harkness LLP
DATE: November 10, 2022
RE: Preliminary Case Assessment — Defense of Whitmore Aerospace LLC in ICC Arbitration Commenced by Kestrel Dynamics GmbH, ICC Case No. 27914/MHM
ENGAGEMENT NO.: 1019-00001
This memorandum is protected by the attorney-client privilege and constitutes attorney work product. It is prepared solely for the use of the attorneys and partners of Calderwood & Harkness LLP in connection with the defense of Whitmore Aerospace LLC in the above-referenced arbitration. It should not be disclosed to any third party without the express written consent of the undersigned and the client's General Counsel.
Right-click to update Table of Contents
I. EXECUTIVE SUMMARY
Calderwood & Harkness LLP has been retained by Whitmore Aerospace LLC ("WAL"), a Delaware limited liability company headquartered at 4200 Wilson Boulevard, Suite 1100, Arlington, VA 22203, to defend against claims brought by Kestrel Dynamics GmbH ("Kestrel"), a German Gesellschaft mit beschränkter Haftung registered at Industriestraße 88, 70565 Stuttgart, Germany (HRB 745621, Amtsgericht Stuttgart), in an arbitration proceeding administered by the International Chamber of Commerce. Kestrel filed its Request for Arbitration with the ICC International Court of Arbitration on November 7, 2022, and the matter has been assigned ICC Case No. 27914/MHM.
Kestrel alleges that WAL materially breached the Master Supply Agreement for Titanium Alloy Turbine Housings dated June 15, 2018 (the "MSA," internal reference WAL-KDG-MSA-2018-0615) through (i) the alleged wrongful rejection of fourteen lots of turbine housings between March and September 2022, and (ii) the issuance of a Notice of Termination for Cause on October 3, 2022. Kestrel seeks approximately €47.3 million in damages, encompassing lost profits for the remainder of the MSA term and two optional renewal periods, unreimbursed rework costs, and purported reputational damages.
Based on our initial review of the MSA, its two amendments, the lot-rejection documentation, the cure correspondence, and the internal quality-control records provided by WAL's General Counsel, Dana Prescott, we conclude that WAL has strong defenses grounded in the following:
(a) The Contractual Rejection and Cure Framework. WAL's rejections were based on documented porosity exceedances measured through standardized incoming inspection procedures. The MSA's Persistent Quality Failure mechanism at § 8.4 provides a clear, objective, and self-executing trigger for termination, and the factual record demonstrates that Kestrel exceeded this threshold by a wide margin.
(b) The Consequential Damages Waiver. Section 8.7 of the MSA expressly waives consequential damages and limits the buyer's remedy to replacement, credit, or termination upon Persistent Quality Failure. This provision bars the vast majority of Kestrel's claimed damages, including lost profits and reputational damages.
(c) The Factual Record of Quality Failures. The porosity data from WAL's incoming inspection under WAL-QCP-100 demonstrates that the rejected lots exceeded the contractual porosity limit of ≤0.25% as specified in WAL-SPEC-TH-401, Appendix C, Table 3. Independent metallurgical testing, which we recommend be conducted promptly, is expected to corroborate WAL's inspection results.
In addition to its defenses, WAL has a viable counterclaim for replacement-component cost premiums incurred in sourcing from the alternative supplier, Valkyr Precision Components Inc. We estimate the counterclaim at approximately €5.17 million, net of Valkyr's introductory discount.
Kestrel is represented by Haber Reinhardt Schlosser Partnerschaft mbB ("HRS"), a Stuttgart-based partnership with a London office, led by Dr. Maximilian Haber (Partner, international arbitration and commercial litigation) and Senior Associate Katrin Schäfer. HRS has a recognized practice in international commercial arbitration and aerospace-sector disputes; we have encountered the firm in prior matters and consider them capable and well-resourced adversaries.
The arbitration is governed by the ICC Rules of Arbitration (2021 edition). The seat of arbitration is New York, New York. The language of the arbitration is English. The governing law of the MSA is the law of the State of New York (§ 22.1). The arbitration clause is found at § 22.3 of the MSA and provides for a three-member tribunal, with each party nominating one co-arbitrator and the presiding arbitrator to be appointed by agreement of the parties or, failing such agreement, by the ICC Court.
This memorandum sets forth our preliminary case assessment, including an analysis of the parties, the relevant contractual provisions, the factual background, Kestrel's claims, WAL's defenses and potential counterclaim, procedural considerations, lender and insurance issues, expert retention recommendations, a preliminary risk assessment, and recommended immediate next steps.
II. THE PARTIES
A. Whitmore Aerospace LLC (Client / Respondent)
Whitmore Aerospace LLC is a Delaware limited liability company engaged in the design, manufacture, and sale of aerospace and defense propulsion systems and structural airframe components for both military and commercial aviation applications. The company's products are supplied to major airframe and engine manufacturers, including leading defense prime contractors and commercial aviation OEMs. WAL maintains its principal executive offices at 4200 Wilson Boulevard, Suite 1100, Arlington, Virginia 22203, and its primary manufacturing and delivery facility is located at 8500 Coppermine Road, Manassas, Virginia 20110. The company's registered agent for service of process in the State of Delaware is located at 1209 Orange Street, Wilmington, Delaware 19801.
For fiscal year 2022, WAL reported annual revenue of approximately $1.87 billion and employed approximately 6,400 individuals across its corporate offices, manufacturing facilities, and field operations. WAL is privately held and has been under the operational leadership of Marcus J. Whitmore III, grandson of the company's founder, who has served as Chief Executive Officer since 2014.
The following individuals within WAL are of particular relevance to this matter:
• Marcus J. Whitmore III, Chief Executive Officer. While Mr. Whitmore was not personally involved in the day-to-day quality-control decisions at issue, he was briefed on the accumulation of rejected lots and the decision to terminate the MSA. His involvement was primarily at the strategic level.
• Dana Prescott, Vice President and General Counsel. Ms. Prescott joined WAL in 2018 and has served as the company's chief legal officer throughout the entire term of the MSA. She reviewed and approved the Notice of Termination for Cause issued on October 3, 2022, and has been the primary point of contact for Calderwood & Harkness in this engagement. Ms. Prescott is a key custodian of relevant documents and communications.
• Gerald Huang, Vice President, Global Supply Chain Operations. Mr. Huang is responsible for procurement and vendor management across WAL's supply chain and was the principal WAL executive responsible for managing the Kestrel relationship. He authored the Notice of Termination for Cause and will serve as a key fact witness on the sequence of rejections, cure failures, the decision to engage Valkyr Precision Components Inc. as a replacement supplier, and the commercial necessity of the termination.
• Dr. Ingrid Vollmer, Senior Vice President, Engineering and Manufacturing. Dr. Vollmer oversees all quality-control processes at WAL's Manassas facility, including the incoming inspection procedures under WAL-QCP-100 that formed the basis for the lot rejections. She supervised the quality-control engineers who conducted the porosity testing and will serve as a key fact witness on the technical aspects of the rejections and the application of the contractual specifications.
B. Kestrel Dynamics GmbH (Claimant)
Kestrel Dynamics GmbH is a German Gesellschaft mit beschränkter Haftung registered at Industriestraße 88, 70565 Stuttgart, Germany (commercial register number HRB 745621, Amtsgericht Stuttgart). Kestrel specializes in the precision machining of aerospace components, with a particular focus on titanium and nickel-alloy turbine housings and high-temperature exhaust assemblies. The company supplies components to a range of European and North American aerospace manufacturers and has established a market position as a mid-tier supplier of precision-machined titanium parts.
For fiscal year 2022, Kestrel reported annual revenue of approximately €312 million and employed approximately 1,800 individuals, primarily at its Stuttgart-area manufacturing facilities. The company was co-founded in 2004 and is led by Friedrich Brenner, who has served as Managing Director (Geschäftsführer) since the company's founding.
The following Kestrel personnel are anticipated to be material to the arbitration:
• Friedrich Brenner, Managing Director (Geschäftsführer) and co-founder. Mr. Brenner is the senior executive responsible for Kestrel's overall business strategy and is expected to provide testimony regarding the company's expectations under the MSA and the alleged financial impact of the termination.
• Luisa Erdmann, Commercial Director. Ms. Erdmann is responsible for international sales and contract management and was the primary Kestrel contact for commercial discussions with WAL throughout the MSA term. She is anticipated to testify regarding the commercial negotiations, amendment discussions, and the events leading up to the termination.
• Dr. Stefan Voss, Head of Quality Assurance. Dr. Voss is anticipated to be Kestrel's primary fact witness on the technical and quality-control aspects of the dispute. He is expected to testify regarding Kestrel's manufacturing processes, quality-assurance procedures, the alleged compliance of the rejected lots with contractual specifications, and the cure efforts undertaken by Kestrel following each rejection.
C. Opposing Counsel
Kestrel is represented by Haber Reinhardt Schlosser Partnerschaft mbB, a partnership organized under German law, with its principal offices at Königstraße 35, 70173 Stuttgart, Germany, and a London office at 30 St Mary Axe, London EC3A 8BF, United Kingdom.
• Dr. Maximilian Haber, Lead Partner. Dr. Haber is a partner in the firm's international arbitration and commercial litigation practice group. He is recognized as a leading practitioner in German and international commercial arbitration and has represented aerospace and automotive industry clients in prior ICC and DIS proceedings. Our research indicates that Dr. Haber has appeared as counsel in at least seven ICC arbitrations over the past decade, several of which involved supply-agreement disputes in the manufacturing sector.
• Katrin Schäfer, Senior Associate. Ms. Schäfer practices in the firm's international arbitration group and is expected to handle the day-to-day case management, including document production, witness-statement preparation, and procedural submissions.
HRS is a well-regarded firm within the German commercial arbitration community. While not among the largest international arbitration practices, the firm has a solid reputation for thorough preparation and aggressive advocacy. We should anticipate well-crafted submissions and a strategic approach to the presentation of Kestrel's case.
III. THE MASTER SUPPLY AGREEMENT — KEY PROVISIONS
The following analysis summarizes the provisions of the MSA most relevant to WAL's defense and the assessment of Kestrel's claims. Page and section references are to the MSA as executed on June 15, 2018, as amended by Amendment No. 1 (February 10, 2020) and Amendment No. 2 (September 3, 2021).
A. Overview and Scope
The MSA is titled "Master Supply Agreement for Titanium Alloy Turbine Housings" and was executed on June 15, 2018, between WAL as Buyer and Kestrel as Seller. The agreement establishes a long-term supply relationship under which Kestrel agreed to manufacture and deliver Ti-6Al-4V ELI (Extra Low Interstitials) titanium alloy turbine housings (the "Products") in accordance with WAL's proprietary engineering specifications designated WAL-SPEC-TH-401 through WAL-SPEC-TH-409. These specifications are incorporated by reference into the MSA at § 3.2 and are attached as Exhibit A to the agreement.
The MSA provides for an initial term of five years, commencing on June 15, 2018, and expiring on June 14, 2023, with two optional one-year renewal periods exercisable solely by WAL upon not less than 90 days' written notice prior to the expiration of the then-current term (§ 2.1). This renewal structure is of critical importance to the damages analysis, as Kestrel's single largest damages component (€27.15 million) rests on the assumption that WAL would have exercised both renewal options — an assumption that is both legally unsupported and commercially speculative.
The delivery terms under the MSA are DDP (Delivered Duty Paid) to WAL's manufacturing facility at 8500 Coppermine Road, Manassas, Virginia 20110, as interpreted in accordance with Incoterms 2020 (§ 6.1). Under this framework, Kestrel bears the risk of loss and the obligation to clear customs and pay all duties and taxes until the Products are delivered at the specified destination.
The MSA imposes rigorous quality standards on Kestrel. Section 7.1 requires Kestrel to maintain AS9100 Revision D certification throughout the term of the agreement. Each lot delivered by Kestrel is subject to incoming inspection by WAL in accordance with WAL's Quality Control Procedure WAL-QCP-100 (§ 7.3). Upon receipt of a lot, WAL has a period of 15 business days to complete its incoming inspection and either accept or reject the lot (§ 7.4). Acceptance within this period constitutes provisional acceptance only, subject to the latent-defect provisions of § 7.6.
B. Volume and Pricing (§§ 4.1, 5.2)
The MSA establishes minimum and maximum annual volume commitments. The minimum annual volume is 2,400 units per contract year (§ 4.1(a)). The maximum annual volume was originally 3,600 units per contract year (§ 4.1(b)) but was increased to 4,000 units per contract year by Amendment No. 1 (discussed below in Section III.G). WAL submits purchase orders on a quarterly basis specifying the number of units and delivery schedule within each quarter, subject to the annual minimum and maximum constraints.
The pricing structure is set forth in § 5.2 and provides for a base unit price with an annual escalator. The base unit price for Contract Year 1 (June 15, 2018, through June 14, 2019) was established at €4,850.00 per unit. The MSA provides for an annual escalator of 2.5%, compounded on the anniversary of the effective date. The resulting unit prices across the five-year term are as follows:
At the minimum annual volume of 2,400 units, the aggregate contract value over the five-year initial term is approximately €61.2 million. At maximum volumes, the aggregate value would be substantially higher. The pricing structure reflects a competitive arrangement for precision-machined Ti-6Al-4V ELI components, and the 2.5% annual escalator tracks broadly with expected cost inflation in the aerospace titanium supply chain.
C. Rejection and Cure (§ 8.4)
Section 8.4 of the MSA establishes the framework for rejection of non-conforming lots and Kestrel's corresponding cure rights. This provision is central to WAL's defense and warrants careful analysis.
Under § 8.4(a), if WAL's incoming inspection under WAL-QCP-100 identifies a non-conformance with any Product specification, WAL is entitled to reject the affected lot in whole or in part by delivering written notice to Kestrel specifying the nature of the non-conformance and the inspection data supporting the rejection.
Upon rejection, § 8.4(b) provides Kestrel with a cure period within which to replace or rework the non-conforming lot at Kestrel's sole cost and expense. The original cure period was 30 calendar days from the date of WAL's rejection notice. This cure period was subsequently extended to 45 calendar days by Amendment No. 2 (September 3, 2021), as discussed below. If Kestrel fails to cure within the applicable cure period, the rejection is deemed an "uncured rejection" under the MSA.
Section 8.4(c) establishes the concept of "Persistent Quality Failure," defined as three or more uncured rejections in any rolling 12-month period. This definition is critical because it provides a clear, objective, and quantitative threshold that, once triggered, activates WAL's enhanced termination rights under § 14.2(b). The Persistent Quality Failure mechanism does not require WAL to demonstrate subjective "material breach" or engage in the often-contentious analysis of whether a breach goes to the essence of the contract. Instead, it provides a self-executing trigger based on measurable, documented quality failures.
For the defense, the Persistent Quality Failure mechanism is the strongest basis for WAL's termination. With seven uncured rejections in the March-to-September 2022 period — more than double the threshold — WAL's invocation of this provision is amply supported by the factual record.
D. Exclusive Remedy and Consequential Damages Waiver (§ 8.7)
Section 8.7 is a critical defensive provision and warrants quotation in relevant part:
"IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, OR EXEMPLARY DAMAGES OF ANY KIND, INCLUDING BUT NOT LIMITED TO LOST PROFITS, LOSS OF BUSINESS, LOSS OF REVENUE, LOSS OF GOODWILL, OR REPUTATIONAL DAMAGES, ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, WHETHER BASED ON WARRANTY, CONTRACT, TORT, STRICT LIABILITY, OR ANY OTHER LEGAL THEORY, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. BUYER'S SOLE AND EXCLUSIVE REMEDY FOR QUALITY FAILURES SHALL BE LIMITED TO (I) REPLACEMENT OR REWORK OF NON-CONFORMING PRODUCTS AT SELLER'S COST, (II) A CREDIT AGAINST FUTURE PURCHASE ORDERS IN AN AMOUNT EQUAL TO THE PURCHASE PRICE OF THE NON-CONFORMING LOT, OR (III) UPON THE OCCURRENCE OF A PERSISTENT QUALITY FAILURE, TERMINATION OF THIS AGREEMENT IN ACCORDANCE WITH SECTION 14.2(b)."
This provision operates as a mutual waiver of consequential damages and, critically, establishes an exclusive remedy for the Buyer in the event of quality failures. The provision is drafted in clear and unambiguous language and is set forth in capitalized text, consistent with the requirements of New York law for conspicuous limitation-of-liability clauses in commercial agreements.
The importance of § 8.7 to WAL's defense cannot be overstated. Kestrel's damages claim of €47.3 million includes approximately €39.98 million in lost profits (both remaining-term and renewal-period) and €3.90 million in reputational damages — categories that are quintessentially consequential damages expressly barred by this provision. If the Tribunal enforces § 8.7 as written, approximately 93% of Kestrel's claimed damages are eliminated.
Under New York law, contractual limitations of liability and consequential damages waivers between sophisticated commercial parties are generally enforceable, provided that the clause is conspicuous and does not contravene public policy. See Metropolitan Life Ins. Co. v. Noble Lowndes Int'l, Inc., 84 N.Y.2d 430, 436 (1994); Biotronik A.G. v. Conor Medsystems Ireland, Ltd., 22 N.Y.3d 799 (2014). We recommend the preparation of a comprehensive legal memorandum on this issue for submission to the Tribunal at the appropriate procedural stage.
E. Termination for Cause (§ 14.2)
Section 14.2 provides two independent grounds for termination for cause:
(a) Material Breach (§ 14.2(a)). Either party may terminate the MSA if the other party commits a material breach that remains uncured for 60 days following written notice specifying the nature of the breach and the required cure. This is a standard termination-for-cause provision that requires the terminating party to demonstrate both materiality and the failure to cure within the notice period.
(b) Persistent Quality Failure (§ 14.2(b)). WAL may terminate the MSA immediately upon written notice to Kestrel if a Persistent Quality Failure has occurred as defined in § 8.4(c) — i.e., three or more uncured rejections in any rolling 12-month period. This provision does not require a separate determination of "material breach" and instead operates as an objective, quantitative termination trigger.
WAL terminated the MSA by Notice of Termination for Cause dated October 3, 2022, invoking § 14.2(b) — Persistent Quality Failure. This is the cleaner basis for termination, as it avoids the subjective and often-litigated question of whether a breach rises to the level of "materiality" under New York law. Instead, it relies on the objective, quantitative threshold established in § 8.4(c), which Kestrel demonstrably exceeded with seven uncured rejections in a rolling 12-month period.
We note that WAL could also have terminated under § 14.2(a) on a material-breach theory, but the Persistent Quality Failure provision provides a more defensible basis because it eliminates the need for the Tribunal to weigh subjective factors such as the "totality of the circumstances" or whether WAL received "substantially what it bargained for." The Persistent Quality Failure route reduces the inquiry to a straightforward factual question: did three or more uncured rejections occur within a rolling 12-month period? The answer, on the current record, is unambiguous.
F. Governing Law and Dispute Resolution (§§ 22.1, 22.3)
Section 22.1 provides that the MSA shall be governed by and construed in accordance with the laws of the State of New York, without regard to its conflicts-of-law principles. New York law is generally favorable to the enforcement of contractual limitations on liability, exclusive-remedy clauses, and consequential damages waivers between sophisticated commercial parties, which supports WAL's defensive posture.
Section 22.3 provides that any dispute arising out of or in connection with the MSA shall be finally resolved by arbitration under the Rules of Arbitration of the International Chamber of Commerce (the "ICC Rules"). The arbitration clause specifies a three-member tribunal, with each party nominating one co-arbitrator. The seat of arbitration is New York, New York, and the language of the arbitration is English. Given the New York seat, the Federal Arbitration Act, 9 U.S.C. §§ 1–16, governs the enforcement of the arbitration agreement and any judicial proceedings ancillary to the arbitration, including motions to compel arbitration or to confirm, vacate, or modify an arbitral award.
G. Amendments. The MSA has been amended twice during its term:
Amendment No. 1 (executed February 10, 2020): This amendment expanded the scope of the Products to include a new high-temperature variant specified under WAL-SPEC-TH-410, which was added to the existing specification set (WAL-SPEC-TH-401 through WAL-SPEC-TH-409). Amendment No. 1 also increased the maximum annual volume from 3,600 units to 4,000 units per contract year to accommodate anticipated demand for the new high-temperature variant. All other terms and conditions of the MSA remained unchanged.
Amendment No. 2 (executed September 3, 2021): This amendment was negotiated in the context of ongoing COVID-19 pandemic-related supply-chain disruptions. It extended the cure period under § 8.4(b) from 30 calendar days to 45 calendar days in recognition of logistics challenges affecting the timely replacement or rework of non-conforming lots. Amendment No. 2 also added a force majeure carve-out specifically addressing pandemic-related delays, providing that neither party would be liable for delay in performance to the extent caused by government-mandated lockdowns, quarantine restrictions, or material disruptions to international freight transportation directly attributable to the COVID-19 pandemic. All other terms and conditions of the MSA, as previously amended, remained unchanged.
The extension of the cure period through Amendment No. 2 is notable in the context of WAL's defense: WAL agreed to provide Kestrel with additional time to cure quality failures — a concession that underscores WAL's good faith in administering the contractual relationship. Despite this extended cure period, Kestrel still failed to cure seven of the fourteen rejected lots within the 45-day window.
IV. FACTUAL BACKGROUND — THE QUALITY DISPUTES AND TERMINATION
A. The Rejected Lots
Between March 7, 2022, and September 19, 2022 — a span of approximately six and a half months — WAL rejected a total of 14 lots totaling 1,680 units of Ti-6Al-4V ELI titanium alloy turbine housings delivered by Kestrel under the MSA.
Each rejection was based on WAL's incoming inspection conducted in accordance with WAL-QCP-100, the company's standardized quality-control procedure for incoming materials and components. The inspections detected porosity levels in the delivered Products that exceeded the contractual specification of ≤0.25%, as set forth in WAL-SPEC-TH-401, Appendix C, Table 3. Porosity — the presence of microscopic voids within the metal structure — is a critical quality parameter for titanium alloy turbine housings because excessive porosity compromises the structural integrity of the component under the extreme thermal and mechanical stress conditions encountered in turbine applications. The ≤0.25% porosity limit in WAL-SPEC-TH-401 is a well-established threshold in the aerospace titanium manufacturing industry and reflects the engineering requirements for the specific turbine-housing applications in which WAL deploys these components.
According to preliminary data provided by WAL's quality-control team under Dr. Ingrid Vollmer's supervision, the porosity levels measured in the 14 rejected lots ranged from 0.19% to 0.38%. This range is significant and requires careful attention. While the upper end of the range (lots with porosity at 0.30%–0.38%) clearly and substantially exceeds the ≤0.25% contractual limit, certain lots at the lower end of the range (specifically, those with measured porosity between 0.19% and 0.25%) fall at or marginally below the contractual threshold. This fact presents a potential vulnerability, discussed in greater detail in Section XI below, if Kestrel argues that WAL applied an unpublished, more restrictive porosity tolerance of ≤0.15% rather than the contractual ≤0.25%.
It is essential that we obtain and review the complete inspection data for each of the 14 rejected lots, including the raw porosity measurements, the testing methodologies employed, the calibration records for the testing equipment, and the identities and qualifications of the inspectors who conducted the testing. We understand from Dr. Vollmer that all inspection data was recorded contemporaneously in WAL's electronic quality-management system and that complete records are available. Independent verification by a metallurgical expert is recommended, as discussed in Section X.B.
B. Cure Failures
Of the 14 lots rejected by WAL, Kestrel failed to cure 7 within the 45-calendar-day amended cure period established by § 8.4(b) as modified by Amendment No. 2. For each of these seven lots, WAL issued a rejection notice specifying the nature of the non-conformance and the applicable cure deadline, and Kestrel either failed to deliver replacement units within the cure period or delivered replacement units that themselves failed WAL's incoming inspection.
The remaining seven lots were either cured by Kestrel within the 45-day period (through delivery of compliant replacement units) or are still within the cure period as of the date of this memorandum. We are in the process of confirming the precise cure status of each lot with Gerald Huang's team.
The seven uncured rejections substantially exceeded the Persistent Quality Failure threshold established in § 8.4(c), which requires only three uncured rejections in a rolling 12-month period. With seven uncured rejections in a rolling period of approximately six and a half months, WAL exceeded the threshold by more than double — providing a robust factual foundation for the invocation of the § 14.2(b) termination right.
We note that even if Kestrel were to succeed in challenging some of the rejections (for example, by arguing that certain lots in the 0.19%–0.25% porosity range should have been accepted), WAL would likely still satisfy the Persistent Quality Failure threshold based on the remaining rejections involving porosity levels unambiguously above the ≤0.25% limit. The degree of margin above the threshold provides important insurance against partial success by Kestrel on its wrongful-rejection theory.
C. Notice of Termination
On October 3, 2022, WAL issued a Notice of Termination for Cause to Kestrel, invoking § 14.2(b) of the MSA based on the occurrence of a Persistent Quality Failure as defined in § 8.4(c). The notice was signed by Gerald Huang, Vice President, Global Supply Chain Operations, on behalf of WAL, and was issued after consultation with Dana Prescott (General Counsel) and Dr. Ingrid Vollmer (SVP Engineering & Manufacturing).
The Notice of Termination identified each of the uncured rejections by lot number, date of rejection, nature of the non-conformance, and the expiration date of the applicable 45-day cure period. The notice stated that the accumulation of seven uncured rejections within a rolling 12-month period constituted a Persistent Quality Failure under § 8.4(c) and that WAL was exercising its right to terminate the MSA for cause under § 14.2(b), effective immediately.
We have reviewed a copy of the Notice of Termination and consider it to be procedurally adequate. The notice identifies the specific contractual provisions under which termination is being exercised, references the factual predicate for the termination (the uncured rejections), and was delivered to Kestrel's designated notice address as specified in the MSA. We recommend confirming the method and date of delivery (tracking and proof of receipt) to foreclose any procedural challenge by Kestrel.
D. Replacement Supplier — Valkyr Precision Components Inc.
Following the accumulation of quality failures by Kestrel and in advance of formal termination, WAL began the process of onboarding Valkyr Precision Components Inc. ("Valkyr"), located at 4401 East Irvington Road, Tucson, Arizona 85714, as a replacement supplier for titanium alloy turbine housings.
Valkyr is an AS9100 Rev D–certified precision-machining company that specializes in aerospace-grade titanium and specialty-alloy components. WAL selected Valkyr following an expedited qualification process driven by the urgent need to secure an alternative supply source for turbine housings critical to WAL's ongoing production commitments to its own downstream customers.
Valkyr's unit price for the Ti-6Al-4V ELI turbine housings conforming to WAL's specifications is €8,432.92 per unit — significantly higher than Kestrel's CY4 price of €5,222.92 per unit. This represents a per-unit premium of approximately €3,210. The price differential reflects the expedited nature of the onboarding, the limited number of qualified suppliers of aerospace-grade precision-machined titanium alloy components, and the higher labor and overhead costs at Valkyr's Tucson facility relative to Kestrel's Stuttgart operations. Valkyr offered an introductory discount of 4.2% on the initial purchase orders, which partially offsets the premium.
WAL's decision to engage Valkyr was a commercially reasonable mitigation step taken in direct response to Kestrel's escalating quality failures. The engagement of an alternative supplier was a prudent and necessary action to ensure the continuity of WAL's manufacturing operations and its ability to fulfill delivery commitments to its own customers. Kestrel is expected to argue that WAL's early engagement of Valkyr — prior to the formal issuance of the Notice of Termination — evidences a pretext for termination and demonstrates that WAL had already decided to exit the Kestrel relationship for reasons unrelated to quality. This argument is addressed in our defense analysis below. The timeline of events, including the progressive accumulation of rejected lots and the correspondence between WAL and Kestrel regarding cure efforts, should demonstrate that the Valkyr engagement was a commercially justified response to a deteriorating supply situation.
V. KESTREL'S CLAIMS — ANALYSIS AND ASSESSMENT
A. Overview of Claimed Damages: €47.3 Million
In its Request for Arbitration filed November 7, 2022, Kestrel alleges that WAL committed a material breach of the MSA on two grounds:
(i) the alleged wrongful rejection of 14 lots comprising 1,680 units of turbine housings between March and September 2022, on the basis that the Products conformed to contractual specifications and that WAL's rejections were based on testing irregularities or the application of standards more stringent than those set forth in the MSA; and
(ii) the issuance of the Notice of Termination for Cause on October 3, 2022, based on allegedly fabricated or exaggerated quality deficiencies, constituting a wrongful termination of the MSA.
Kestrel claims total damages of approximately €47.3 million, broken down into four categories discussed in detail below.
B. Lost Profits — Remaining MSA Term (CY5): €12.83 Million
Kestrel claims lost profits for the remainder of Contract Year 5 of the MSA (from the termination date through June 14, 2023), calculated on the basis of 3,600 units at the CY5 unit price of €5,353.49, multiplied by Kestrel's claimed gross margin of 22.4%. Based on Kestrel's Request for Arbitration, the calculation is as follows:
3,600 units × €5,353.49 = €19,272,564 (projected revenue) €19,272,564 × 22.4% = €4,317,054 (claimed lost profit on CY5)
The €12.83 million figure stated in Kestrel's Request appears to represent lost profits for the entire CY5 at a higher assumed volume, or may incorporate additional categories of direct damages not yet fully disaggregated in the filing. We are in the process of obtaining Kestrel's detailed damages calculations and supporting financial data through the arbitration process and will revise our analysis accordingly.
Assessment: This claim is vulnerable on multiple grounds:
First, the consequential damages waiver in § 8.7 expressly bars the recovery of lost profits. Lost profits are the prototypical category of consequential damages, and § 8.7 specifically identifies "lost profits" among the categories of damages that are waived. Under New York law, a mutual waiver of this nature between sophisticated commercial parties is presumptively enforceable.
Second, even in the absence of the contractual waiver, Kestrel would need to demonstrate that the termination was wrongful — that is, that WAL's invocation of § 14.2(b) was not justified by the factual record. Given the seven uncured rejections (against a threshold of three), Kestrel faces a steep burden.
Third, Kestrel's claimed margin of 22.4% appears inflated relative to industry benchmarks for precision-machined titanium alloy aerospace components. We recommend the engagement of forensic accountants to analyze Kestrel's margin assumptions. Preliminarily, we have identified Canfield & Thorpe LLP (Sandra Gillespie, CPA/ABV, 1345 Avenue of the Americas, New York, NY 10105) as a qualified forensic accounting firm for this engagement. A detailed analysis of Kestrel's cost structure, allocation methodologies, and financial projections will be essential to rebutting the claimed margin.
C. Lost Profits — Renewal Terms: €27.15 Million
Kestrel claims lost profits for the two optional one-year renewal periods of the MSA, constituting the largest single component of its damages claim at €27.15 million. This claim is premised on the assumption that WAL would have exercised both renewal options and that Kestrel would have continued to supply Products at the escalating contract prices and at the claimed 22.4% margin.
Assessment: This claim is highly aggressive and, in our view, likely to fail:
First, the renewal options under § 2.1 were exercisable solely at WAL's discretion. The MSA imposed no obligation on WAL to renew, and WAL had unfettered discretion to allow the MSA to expire at the end of the initial five-year term. Kestrel had no contractual entitlement to renewal and no basis to assume that renewal would occur.
Second, under New York law, a party has no legally cognizable expectation interest in profits that would have been earned during a discretionary renewal period. The mere existence of a renewal option does not create an enforceable right to the benefits that would flow from the exercise of that option. Kestrel's claim to renewal-period lost profits is therefore legally deficient as a matter of substantive contract law, entirely apart from the consequential damages waiver. See, e.g., Kenford Co. v. County of Erie, 73 N.Y.2d 312, 319 (1989) (lost profits must be within the contemplation of the parties and proved with reasonable certainty); see also Tractebel Energy Mktg., Inc. v. AEP Power Mktg., Inc., 487 F.3d 89, 110 (2d Cir. 2007).
Third, as with the CY5 lost-profit claim, this claim is independently barred by the § 8.7 consequential damages waiver.
Fourth, even if Kestrel could overcome the contractual and legal barriers, the speculative nature of projecting profits over two hypothetical renewal years — based on assumptions about volume, pricing, margins, competitive conditions, and WAL's exercise of a discretionary option — presents significant evidentiary challenges under New York law's requirement that lost profits be proved with "reasonable certainty."
We consider the renewal-period lost-profits claim to be the most vulnerable component of Kestrel's overall damages theory and recommend targeted briefing on this issue at the earliest opportunity.
D. Unreimbursed Rework Costs: €3.42 Million
Kestrel claims €3.42 million in unreimbursed costs incurred in attempting to cure the rejected lots, including the costs of rework, replacement materials, expedited shipping, and quality-assurance retesting.
Assessment: This claim is partially defensible by Kestrel if it can demonstrate that cure attempts were made in good faith and at material cost, but it is subject to challenge on several grounds:
First, Kestrel failed to cure 7 of the 14 rejected lots. The failure to achieve a successful cure — despite the expenditure of rework costs — undermines Kestrel's implicit argument that the Products were in conformance and that WAL's rejections were baseless. If the Products genuinely conformed to the contractual specifications, one would expect the rework process to readily resolve any marginal deviations.
Second, the rework costs may be classified as consequential or incidental damages barred by the § 8.7 waiver. Whether rework costs fall within the scope of the waiver is a question that will require further legal analysis, as Kestrel may argue that rework costs are a form of reliance damages or direct damages rather than consequential damages. The characterization of rework costs under New York law is fact-dependent and may turn on the specific language of § 8.7.
Third, even if the rework costs are not categorically barred by the waiver, WAL can argue that Kestrel assumed the risk of cure costs under the MSA's allocation of responsibilities. Section 8.4(b) expressly provides that replacement or rework is to be performed "at Seller's sole cost and expense." The MSA thus contemplates that Kestrel bears the financial risk of cure — not that WAL will reimburse Kestrel for the costs of curing its own quality failures.
Fourth, the quantum of claimed rework costs (€3.42 million for approximately 1,680 units) warrants scrutiny. At approximately €2,036 per unit, the claimed rework costs represent a significant proportion of the unit price (approximately 39% of the CY4 price). This level of rework expenditure may indicate either that the quality failures were genuine and systemic (supporting WAL's defense) or that Kestrel is inflating its rework-cost calculations.
E. Reputational Damages: €3.90 Million
Kestrel claims €3.90 million in alleged reputational damages, asserting that WAL's termination of the MSA has caused Kestrel to suffer loss of business opportunities and reputational harm in the aerospace supply market.
Assessment: This is the weakest component of Kestrel's damages claim:
First, reputational damages are inherently speculative and difficult to quantify with the reasonable certainty required under New York law. The claim requires Kestrel to establish a causal link between WAL's termination and specific, identifiable lost business opportunities — a burden that is typically extremely difficult to satisfy, particularly in the aerospace supply chain, where procurement decisions are driven by technical qualification, pricing, and capacity considerations rather than by the reputational implications of a single contract termination.
Second, reputational damages are expressly barred by the § 8.7 consequential damages waiver, which specifically enumerates "loss of goodwill" and "reputational damages" among the waived categories.
Third, Kestrel would need to demonstrate that specific potential customers or contracts were lost as a direct result of WAL's termination — rather than as a result of Kestrel's own quality-control issues, which independently would give pause to prospective customers conducting supplier qualification reviews. If the quality failures are substantiated, Kestrel's reputational harm flows from its own manufacturing deficiencies, not from WAL's decision to terminate.
Fourth, the claimed amount of €3.90 million is presented without any evident methodology or factual basis in Kestrel's Request for Arbitration. We anticipate pressing for detailed disclosure of the basis for this claim during document production.
VI. WAL'S DEFENSES — SUMMARY
Based on our preliminary review, WAL has four principal lines of defense, each of which is grounded in either the express terms of the MSA, the factual record, or established principles of New York law.
A. The Rejections Were Justified
The core factual defense is straightforward: WAL rejected the 14 lots because they failed to meet the contractual porosity specification. The porosity levels in the rejected lots ranged from 0.19% to 0.38%, and the contractual specification in WAL-SPEC-TH-401, Appendix C, Table 3, establishes a maximum permissible porosity of ≤0.25%. The lots with measured porosity above 0.25% were clearly non-conforming under the express terms of the specification.
We recommend the retention of an independent metallurgical expert to confirm WAL's porosity data through independent testing of retained samples from the rejected lots and to provide expert testimony regarding the reliability of WAL's testing methodologies and the significance of the porosity exceedances for turbine-housing performance and safety. We have preliminarily identified Dr. Raymond Chow, Principal Engineer at Arclight Materials Science Inc. (7900 Westpark Drive, Suite 200, McLean, Virginia 22102), as a qualified expert for this engagement. Dr. Chow has extensive experience in titanium alloy metallurgy and has served as a testifying expert in prior aerospace quality-control disputes.
Kestrel's anticipated argument — that WAL applied an unpublished porosity tolerance of ≤0.15% rather than the contractual ≤0.25% — is factually incorrect based on the information currently available to us. The ≤0.25% limit is expressly stated in WAL-SPEC-TH-401, Appendix C, Table 3, and WAL's rejection notices reference this specification. However, we must carefully examine the internal documentation from WAL's quality-control team to confirm that no internal guidance, memoranda, or informal practices suggest the application of a more restrictive standard. If any such documentation exists, it must be identified and addressed proactively rather than disclosed for the first time during document production.
We do note the potential vulnerability created by the lots with measured porosity between 0.19% and 0.25%. If these lots were in fact at or below the ≤0.25% contractual threshold, the basis for their rejection requires further investigation. It is possible that the porosity measurements reflect testing variability, measurement uncertainty, or a reading protocol under which WAL rounded or applied a margin of error. These technical details must be carefully developed with Dr. Vollmer and the quality-control engineers who conducted the testing.
B. Termination Was Procedurally and Substantively Proper
WAL's termination of the MSA was both procedurally and substantively proper under the terms of the agreement.
Substantively, seven uncured rejections in a rolling period of approximately six and a half months (March through September 2022) far exceeded the Persistent Quality Failure threshold of three uncured rejections in a rolling 12-month period under § 8.4(c). The factual predicate for termination under § 14.2(b) was amply satisfied — indeed, the record shows more than double the required minimum number of uncured rejections, in less than half the rolling-period window.
Procedurally, WAL's October 3, 2022 Notice of Termination was issued in the form required by the MSA, referencing the applicable contract provisions (§§ 8.4(c) and 14.2(b)), identifying the specific uncured rejections that constituted the Persistent Quality Failure, and delivered to Kestrel's designated notice address. The notice was signed by Gerald Huang in his capacity as VP Global Supply Chain Operations, which is within the scope of authorized signatories under the MSA's notice provisions.
Moreover, we note that even for those lots where Kestrel did attempt a cure, five of the seven uncured lots reflect complete failure to deliver replacement units within the 45-day amended cure period. This pattern provides further evidence that Kestrel's quality failures were systemic in nature — not isolated or marginal deviations that could readily be corrected through routine rework.
C. Consequential Damages Waiver Bars the Majority of Kestrel's Claims
As discussed in detail in Section III.D above, § 8.7 of the MSA operates as a mutual waiver of consequential damages and limits WAL's remedy for quality failures to replacement, credit, or termination upon Persistent Quality Failure.
The practical effect of this provision on Kestrel's damages claim is dramatic:
Under New York law, contractual limitations of liability between sophisticated commercial parties are generally enforceable. The relevant inquiry is whether the clause is conspicuous, negotiated at arm's length between parties of comparable sophistication and bargaining power, and not unconscionable or contrary to public policy. See Metropolitan Life Ins. Co. v. Noble Lowndes Int'l, Inc., 84 N.Y.2d 430, 436 (1994). Both WAL and Kestrel are substantial commercial enterprises — WAL with $1.87 billion in annual revenue and Kestrel with €312 million — and the MSA was a negotiated agreement between represented parties. The § 8.7 waiver is set forth in capitalized text in a separately referenced section of the agreement, satisfying the conspicuousness requirement.
We recommend the preparation of a comprehensive legal memorandum addressing the enforceability of § 8.7 under New York law, including a survey of relevant case law, the application of the unconscionability defense (which we expect Kestrel to raise), and the treatment of contractual liability limitations in international commercial arbitration under the ICC Rules.
D. Replacement-Supplier Decision Was Commercially Reasonable Mitigation
Kestrel is expected to argue that WAL's engagement of Valkyr prior to the formal issuance of the Notice of Termination demonstrates that the termination was pretextual — that WAL had already decided to exit the Kestrel relationship for reasons unrelated to quality and manufactured the quality-based termination as a justification.
This argument should be rebutted by the following evidence:
(i) Timeline. WAL began exploring alternative suppliers only after the accumulation of multiple rejected lots, and the Valkyr engagement was initiated in response to the pressing commercial need to secure an alternative source of turbine housings for WAL's ongoing production commitments. The timeline of Valkyr engagement relative to the progressive accumulation of rejected lots should be carefully documented and presented.
(ii) Commercial Necessity. WAL's downstream customers (including defense prime contractors subject to strict delivery schedules) could not tolerate the supply uncertainty created by Kestrel's escalating quality failures. Gerald Huang can testify to the commercial necessity of securing an alternative supply source and the consequences that WAL would have faced if it had not done so.
(iii) Mitigation Obligation. Under New York law, a non-breaching party has a duty to mitigate damages. WAL's proactive engagement of an alternative supplier is consistent with this obligation and cannot be characterized as bad faith.
(iv) Price Premium. The fact that Valkyr's unit price (€8,432.92) is substantially higher than Kestrel's (€5,222.92) undermines any suggestion that WAL was motivated by a desire to find a cheaper supplier. WAL incurred a significant cost premium by engaging Valkyr — precisely the opposite of what one would expect if the termination were pretextual.
VII. POTENTIAL COUNTERCLAIM
A. Replacement-Component Cost Premium
WAL incurred substantial additional costs as a direct result of Kestrel's quality failures and the need to source replacement turbine housings from Valkyr at a significantly higher unit price. We recommend asserting a counterclaim for the replacement-component cost premium in WAL's Answer.
The calculation of the counterclaim is as follows:
• Number of units sourced from Valkyr to replace the rejected Kestrel lots: 1,680 units
• Valkyr unit price: €8,432.92
• Kestrel CY4 unit price (the price that would have applied but for Kestrel's breach): €5,222.92
• Per-unit cost premium: €8,432.92 − €5,222.92 = €3,210.00
• Gross replacement cost premium: 1,680 × €3,210.00 = €5,392,800 (rounded to €5,393,280 based on precise arithmetic)
• Less Valkyr introductory discount of 4.2%: €5,393,280 × (1 − 0.042) = €5,393,280 × 0.958 = €5,166,762.24
• Net replacement cost premium: approximately €5.17 million
We recommend asserting this counterclaim at €5.17 million (or such higher amount as may be supported by the final replacement-unit accounting) in WAL's Answer and Counterclaim. The counterclaim is straightforward: Kestrel's failure to deliver conforming Products necessitated WAL's sourcing from a higher-cost replacement supplier, and the price differential between the Valkyr price and the Kestrel price represents direct damages flowing from Kestrel's breach of the quality and delivery obligations of the MSA. This is a standard cover-price damages theory under both common law and UCC § 2-712 (to the extent applicable by analogy, as the MSA is governed by New York law and the Products are goods).
B. Potential Defenses to Counterclaim
Kestrel may raise the following defenses to WAL's counterclaim:
First, Kestrel may argue that WAL failed to mitigate by not seeking competitive bids from other qualified suppliers before engaging Valkyr, and that WAL's acceptance of Valkyr's pricing without conducting a competitive procurement process resulted in an unreasonably high replacement cost.
Second, Kestrel may challenge the reasonableness of Valkyr's pricing, arguing that the €8,432.92 unit price is above market rates and that WAL should have been able to source replacement components at a lower cost.
Both of these defenses are addressable with evidence of the following:
(i) The limited number of qualified suppliers of precision-machined aerospace-grade Ti-6Al-4V ELI titanium alloy turbine housings. The aerospace titanium supply chain is highly concentrated, and the number of AS9100 Rev D–certified suppliers with the technical capability, capacity, and qualification to produce components to WAL's specifications is small. Gerald Huang can testify to the limited supplier pool and the qualification requirements that constrain WAL's sourcing options.
(ii) The urgency of WAL's supply needs. WAL could not afford to conduct a protracted competitive-bid process while its production lines were being disrupted by Kestrel's quality failures and its downstream customers were awaiting deliveries. The time required to qualify a new supplier — including facility audits, first-article inspections, and production validation — typically extends over several months in the aerospace industry, and Valkyr's prior qualification status (as a backup supplier already known to WAL) made it the most immediately available option.
(iii) Valkyr's introductory discount of 4.2% demonstrates that WAL did negotiate pricing concessions and did not simply accept Valkyr's initial quoted price without negotiation.
VIII. PROCEDURAL CONSIDERATIONS
A. ICC Arbitration Framework
The arbitration is conducted under the ICC Rules of Arbitration (2021 edition). The key procedural parameters are as follows:
• Tribunal composition: Three-member tribunal, with each party nominating one co-arbitrator and the presiding arbitrator to be appointed by agreement of the two co-arbitrators (or, failing agreement, by the ICC Court).
• Seat of arbitration: New York, New York. The New York seat means that the FAA governs the enforcement and judicial review of the arbitration, and that any challenge to the final award would be brought before the United States District Court for the Southern District of New York under the FAA's limited grounds for vacatur (9 U.S.C. § 10).
• Language of the arbitration: English. All submissions, witness statements, expert reports, and hearing proceedings will be conducted in English. Given that several key Kestrel witnesses (including Friedrich Brenner, Luisa Erdmann, and Dr. Stefan Voss) are German-speaking, interpretation services may be required at the evidentiary hearing.
Co-Arbitrator Nomination. Under the ICC Rules, WAL must nominate its co-arbitrator within the deadline specified in the Rules (typically 30 days from receipt of the Request for Arbitration, which was received on November 7, 2022, establishing a provisional deadline of approximately December 7, 2022). We recommend that WAL's co-arbitrator nomination be made promptly and with care, as the composition of the Tribunal will have a significant impact on the conduct and outcome of the arbitration.
Our initial recommendation is to consider the Honorable Robert A. Castillo, retired judge of the United States District Court for the Southern District of New York, as WAL's co-arbitrator nominee. Judge Castillo (ret.) has substantial experience in complex commercial litigation and international arbitration, and his New York judicial background is well suited to a case governed by New York law and involving sophisticated contractual interpretation issues. This recommendation is subject to a conflict and availability check, which we will initiate immediately upon receiving authorization from the partnership.
The Presiding Arbitrator will be appointed by agreement of the two co-arbitrators or, failing agreement within the time limit set by the ICC Court, by the ICC Court itself. We should be prepared to propose candidates for the presiding arbitrator position and to evaluate any candidates proposed by Kestrel's co-arbitrator or by the ICC Court.
Kestrel's co-arbitrator nominee has not yet been identified, as the Request for Arbitration filed on November 7, 2022, may not yet include Kestrel's nomination. We will review the filing details upon receipt from the ICC Secretariat and advise accordingly.
B. Governing Law
As noted above, the MSA designates the law of the State of New York as the governing law (§ 22.1), without regard to conflicts-of-law principles. New York law is generally favorable to WAL's position for several reasons:
• New York courts consistently enforce contractual limitations on liability, exclusive-remedy clauses, and consequential damages waivers between sophisticated commercial parties, absent unconscionability or public-policy concerns. See Metropolitan Life Ins. Co. v. Noble Lowndes Int'l, Inc., 84 N.Y.2d 430 (1994); Biotronik A.G. v. Conor Medsystems Ireland, Ltd., 22 N.Y.3d 799 (2014).
• New York law provides clear standards for the determination of lost-profits damages, requiring that such damages be proved with "reasonable certainty" and be within the contemplation of the parties at the time of contracting. See Kenford Co. v. County of Erie, 73 N.Y.2d 312 (1989). Kestrel's speculative renewal-period lost-profits claim is unlikely to satisfy this standard.
• New York law recognizes the duty to mitigate damages, which supports WAL's position that its engagement of Valkyr was a reasonable and necessary mitigation step.
The Federal Arbitration Act (9 U.S.C. §§ 1–16) governs the enforcement of the arbitration agreement and the judicial review of the eventual award, given the New York seat. The FAA provides a strong federal policy in favor of arbitration and limits the grounds for vacatur of an arbitral award to the narrow circumstances specified in 9 U.S.C. § 10 (corruption, fraud, evident partiality, exceeding the scope of authority, or other misconduct).
C. Anticipated Timeline
Based on the ICC Rules, the complexity of the dispute, and our experience with comparable ICC arbitrations involving aerospace supply-agreement claims, we anticipate the following procedural timeline:
The full arbitration cycle is estimated at 14 to 18 months from the date of filing, with the evidentiary hearing likely occurring in the first quarter of 2024 and the final award expected by mid-2024. This timeline assumes no significant procedural disputes or bifurcation applications. If either party requests bifurcation (for example, to address the enforceability of the consequential damages waiver as a preliminary issue), the timeline could be extended.
We will provide a more detailed procedural timeline upon the constitution of the Tribunal and the issuance of Procedural Order No. 1.
IX. LENDER AND INSURANCE CONSIDERATIONS
A. Veltrano National Bank, N.A.
WAL maintains a $350 million senior secured revolving credit facility with Veltrano National Bank, N.A. (One Veltrano Center, Charlotte, North Carolina 28255). The credit facility is the company's primary source of working-capital liquidity and is secured by substantially all of WAL's assets.